Overview

Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy Subjects

Status:
Completed

Trial end date:
2018-04-23

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the impact of mild to moderate hepatic impairment on the pharmacokinetics of a single oral dose of Lu AF35700

Phase:

Phase 1

Details

Lead Sponsor:

H. Lundbeck A/S